Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Despite the advances in screening protocols and treatment options, hepatocellular carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver cirrhosis. Moreover, the survival outcomes after failure of first-line therapy for unresectable HCC is still poor with limited...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/8/4/616 |
| _version_ | 1797550625179828224 |
|---|---|
| author | Mohamed A. Abd El Aziz Antonio Facciorusso Tarek Nayfeh Samer Saadi Mohamed Elnaggar Christian Cotsoglou Rodolfo Sacco |
| author_facet | Mohamed A. Abd El Aziz Antonio Facciorusso Tarek Nayfeh Samer Saadi Mohamed Elnaggar Christian Cotsoglou Rodolfo Sacco |
| author_sort | Mohamed A. Abd El Aziz |
| collection | DOAJ |
| description | Despite the advances in screening protocols and treatment options, hepatocellular carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver cirrhosis. Moreover, the survival outcomes after failure of first-line therapy for unresectable HCC is still poor with limited therapeutic options. One of these options is immune checkpoint inhibitors. The aim of this study is to comprehensively review the efficacy and safety of immune checkpoint inhibitors for patients with HCC. |
| first_indexed | 2024-03-10T15:31:57Z |
| format | Article |
| id | doaj.art-e20c243badfa4cf2b71c5eabf7660dd3 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T15:31:57Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-e20c243badfa4cf2b71c5eabf7660dd32023-11-20T17:36:15ZengMDPI AGVaccines2076-393X2020-10-018461610.3390/vaccines8040616Immune Checkpoint Inhibitors for Unresectable Hepatocellular CarcinomaMohamed A. Abd El Aziz0Antonio Facciorusso1Tarek Nayfeh2Samer Saadi3Mohamed Elnaggar4Christian Cotsoglou5Rodolfo Sacco6Department of Surgery, Mayo Clinic, Rochester, MN 55905, USAGastroenterology Unit, Department of Medical Sciences, Ospedali Riuniti di Foggia, 71122 Foggia, ItalyRobert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN 55905, USARobert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN 55905, USADepartment of Internal Medicine, Reno School of Medicine, University of Nevada, Las Vegas, NV 1155, USAGeneral Surgery Department, ASST-Vimercate, 20871 Vimercate, ItalyGastroenterology Unit, Department of Medical Sciences, Ospedali Riuniti di Foggia, 71122 Foggia, ItalyDespite the advances in screening protocols and treatment options, hepatocellular carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver cirrhosis. Moreover, the survival outcomes after failure of first-line therapy for unresectable HCC is still poor with limited therapeutic options. One of these options is immune checkpoint inhibitors. The aim of this study is to comprehensively review the efficacy and safety of immune checkpoint inhibitors for patients with HCC.https://www.mdpi.com/2076-393X/8/4/616HCCCPIimmunotherapysurvivalprogression |
| spellingShingle | Mohamed A. Abd El Aziz Antonio Facciorusso Tarek Nayfeh Samer Saadi Mohamed Elnaggar Christian Cotsoglou Rodolfo Sacco Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Vaccines HCC CPI immunotherapy survival progression |
| title | Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma |
| title_full | Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma |
| title_fullStr | Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma |
| title_full_unstemmed | Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma |
| title_short | Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma |
| title_sort | immune checkpoint inhibitors for unresectable hepatocellular carcinoma |
| topic | HCC CPI immunotherapy survival progression |
| url | https://www.mdpi.com/2076-393X/8/4/616 |
| work_keys_str_mv | AT mohamedaabdelaziz immunecheckpointinhibitorsforunresectablehepatocellularcarcinoma AT antoniofacciorusso immunecheckpointinhibitorsforunresectablehepatocellularcarcinoma AT tareknayfeh immunecheckpointinhibitorsforunresectablehepatocellularcarcinoma AT samersaadi immunecheckpointinhibitorsforunresectablehepatocellularcarcinoma AT mohamedelnaggar immunecheckpointinhibitorsforunresectablehepatocellularcarcinoma AT christiancotsoglou immunecheckpointinhibitorsforunresectablehepatocellularcarcinoma AT rodolfosacco immunecheckpointinhibitorsforunresectablehepatocellularcarcinoma |